Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1521 to 1530 of 1846 total matches.
Yohimbine for Male Sexual Dysfunction
The Medical Letter on Drugs and Therapeutics • Dec 23, 1994 (Issue 938)
to improvement in sexual function after beginning yohimbine ranged from 3 days to 3 weeks. Some psychiatrists ...
Yohimbine hydrochloride, a presynaptic 2 -adrenergic receptor antagonist available by prescription in the USA (Yocon, Yohimex, and others), is advertised for treatment of impotence and has been used as an aphrodisiac. A pre-1938 drug, yohimbine has never been approved for marketing by the US Food and Drug Administration.
Mycophenolate Mofetil - A New Immunosuppressant for Organ Transplantation
The Medical Letter on Drugs and Therapeutics • Sep 29, 1995 (Issue 958)
/day, in 499 patients receiving a cadaveric renal allograft. All patients received corticosteroids ...
Mycophenolate mofetil (CellCept - Roche) has been approved by the US Food and Drug Administration for oral use in preventing organ rejection in patients receiving allogeneic renal transplants. It is being promoted as an improvement over azathioprine (Imuran) for concurrent use with cyclosporine (Sandimmune; Neoral) and corticosteroids.
Reteplase (Retavase)
The Medical Letter on Drugs and Therapeutics • Feb 28, 1997 (Issue 995)
. The mortality rate 35 days later was 8.9%
with reteplase and 9.4% with streptokinase; after six months ...
Reteplase (Retavase - Boehringer Mannheim), a recombinant protein derivative of human tissue plasminogen activator (t-PA), has been marketed in the USA for thrombolysis in patients with acute myocardial infarction.
Imiquimod for Genital Warts
The Medical Letter on Drugs and Therapeutics • Dec 19, 1997 (Issue 1016)
, applied three days per week, costs $56.64 for a four-week course of treatment, according to wholesale ...
Imiquimod (i mi kwi' mod) 5% cream (Aldara - 3M Pharmaceuticals) has been approved by the FDA for treatment of external genital and perianal warts (condyloma acuminata). The drug requires a prescription but is applied by the patient. It is the second patient-applied treatment to become available for external genital warts; the first was podofilox (Condylox - Medical Letter, 33:117, 1991).
Hyaluronan Injections for Osteoarthritis of the Knee
The Medical Letter on Drugs and Therapeutics • Jul 03, 1998 (Issue 1030)
injections, 44% with naproxen and 38% with saline injections. A published
60-day study in 40 patients ...
Sodium hyaluronate (Hyalgan - Sanofi) and hylan G-F 20 (Synvisc - Wyeth- Ayerst) have been approved by the FDA for intra-articular injections in patients with knee pain due to osteoarthritis. Hylan G-F 20 is a cross-linked derivative of hyaluronic acid with a higher molecular weight than sodium hyaluronate. 'Hyaluronan' refers to either the acid or its salt.
In Brief: Calcium and Vitamin D Supplements
The Medical Letter on Drugs and Therapeutics • Jul 31, 2006 (Issue 1240)
age 50 should have a total calcium intake of about 1200 mg per day (Treat Guidel
Med Lett 2005; 3:69 ...
The results of a randomized, placebo-controlled trial of calcium and vitamin D supplements in more than 36,000 postmenopausal women, conducted as part of the Women’s Health Initiative (RD Jackson et al. N Engl J Med 2006; 354:669), have been misinterpreted by some patients to mean that they should stop taking such supplements.At the time of recruitment, the participants in this study had an average daily calcium intake of 1100-1200 mg. They were randomized to take either 1000 mg of calcium carbonate plus 400 IU of vitamin D3 or a placebo for an average of 7 years. Both groups were permitted...
In Brief: A New Indication for Colesevelam (Welchol)
The Medical Letter on Drugs and Therapeutics • May 05, 2008 (Issue 1285)
colesevelam 3800 mg per day
or placebo; colesevelam significantly reduced glycosylated hemoglobin (A1c ...
Colesevelam (Welchol - Daiichi Sankyo - Med Lett Drugs Ther 2000; 42:102), a bile-acid sequestrant used to lower LDL cholesterol, has been approved by the FDA as an adjunct to diet and exercise in the treatment of type 2 diabetes. In unpublished studies summarized in the package insert, patients with type 2 diabetes taking metformin (Glucophage, and others), a sulfonylurea or insulin (each as either monotherapy or in combination with other anti-diabetic agents) were given colesevelam 3800 mg per day or placebo; colesevelam significantly reduced glycosylated hemoglobin (A1c) by about 0.5% more...
In Brief: Measles Outbreak
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
at
least 28 days apart, with the first dose no earlier than
12 months of age) generally provide lifelong ...
The US Centers for Disease Control and Prevention (CDC) has reported that measles outbreaks have occurred in New York City, California and Arizona in 2008, and additional cases have been confirmed in Michigan, Wisconsin, Hawaii, New York State, Pennsylvania, Illinois and Virginia (CDC Health Advisory, May 1, 2008). To date, 63 of the 64 infected patients were unvaccinated, and 54 of the cases were associated with importation of the disease. Both measles infection and vaccination (2 doses at least 28 days apart, with the first dose no earlier than 12 months of age) generally provide lifelong...
Denosumab (Prolia) for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Oct 18, 2010 (Issue 1349)
of denosumab reach a
maximum in 10 days and remain high enough to inhibit
bone turnover for at least 6 months ...
The FDA has approved use of denosumab (Prolia –
Amgen) for treatment of osteoporosis in postmenopausal
women at high risk for fracture.
Duloxetine (Cymbalta) for Chronic Musculoskeletal Pain
The Medical Letter on Drugs and Therapeutics • May 02, 2011 (Issue 1363)
• May 2, 2011
drug to avoid withdrawal symptoms. A 30-day supply
of Cymbalta 60-mg capsules costs ...
Previously approved by the FDA for treatment of depression, general anxiety disorder, diabetic peripheral
neuropathic pain and fibromyalgia, duloxetine (Cymbalta – Lilly) has now also been approved for
treatment of chronic musculoskeletal pain.